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Abstract 
The inflammasome adaptor ASC contributes to innate immunity through the activation 
of caspase-1. Here we found that signaling pathways dependent on the kinases Syk and 
Jnk were required for the activation of caspase-1 via the ASC-dependent 
inflammasomes NLRP3 and AIM2. Inhibition of Syk or Jnk abolished the formation of 
ASC specks without affecting the interaction of ASC with NLRP3. ASC was 
phosphorylated during inflammasome activation in a Syk- and Jnk-dependent manner, 
which suggested that Syk and Jnk are upstream of ASC phosphorylation. Moreover, 
phosphorylation of Tyr144 in mouse ASC was critical for speck formation and caspase-1 
activation. Our results suggest that phosphorylation of ASC controls inflammasome 





Inflammasomes are large multiprotein oligomers that serve critical roles in host defense 
against microbial pathogens and the development of inflammatory disorders by 
facilitating the secretion of proinflammatory cytokines1. Core components of each 
inflammasome are pro-caspase-1 and a cytosolic pattern-recognition receptor belonging 
to the Nod-like receptor (NLR) family or the HIN-200 family, which contains a pyrin 
domain or a caspase-recruitment domain (CARD). Inflammasome complexes are 
believed to be assembled after the recognition of specific stimuli by the receptors2,3. 
Once assembled, inflammasomes serve as platforms for the activation of caspase-1, 
which in turn cleaves the precursor forms of interleukin-1β (IL-1β) and IL-18 to their 
bioactive forms4. 
Different subsets of inflammasomes are activated by different stimuli. The NLRC4 
inflammasome is activated by flagellin and the type III secretion apparatus from 
bacteria5–7. Anthrax lethal toxin produced by Bacillus anthracistriggers activation of 
the NLRP1B inflammasome in mouse macrophages8. Activation of the NLRP3 
inflammasome depends on a priming step (signal 1) and an activation step (signal 2)9. 
Signal 1 can be induced by signaling via Toll-like receptors, whereas signal 2 is induced 
by microbial components with diverse molecular structures, such as microbial RNA and 
toxins10,11. In addition, the adjuvant alum and endogenous danger-associated molecules, 
including ATP and monosodium urate (MSU) crystals, also induce signal 2 for the 
activation of the NLRP3 inflammasome10,12,13. AIM2 and IFI16 sense cytosolic DNA and 
nuclear DNA, respectively, and DNA viruses14, Francisella tularensis15, Listeria 
monocytogenes16,17 and Streptococcus pneumoniae18 have been demonstrated to activate 
the AIM2 inflammasome or IFI16 inflammasome19 in host cells. 
The adaptor ASC (PYCARD or TMS-1) is composed of a pyrin domain and a CARD 
and contributes to the assembly of inflammasome complexes20. ASC serves as the bridge 
between pro-caspase-1 and pyrin-containing inflammasomes, such as NLRP3 and AIM2. 
Accordingly, NLRP3 and AIM2 require ASC exclusively for the recruitment of 
pro-caspase-1, while the CARD-containing receptors NLRC4 and NLRP1 can directly 
interact with pro-caspase-1 (refs. 1,7,21). During inflammasome activation, ASC also 
forms cytosolic macromolecular aggregates of ASC dimers called ‘ASC specks’, ‘ASC foci’  
or ‘pyroptosomes’22,23. The ASC speck recruits and activates procaspase-1, which leads 
to the secretion of large amounts of IL-1β and IL-18 and to pyroptosis, a form of 
programmed cell death. However, ASC is not always essential for cytokine processing 
and the induction of pyroptosis via the NLRC4 inflammasome. In addition to 
protein-protein interactions in inflammasome complexes, published reports have 
revealed the involvement of type I interferons15,24, the ubiquitin ligase–associated 
protein SGT1, the heat-shock protein hsp90 (ref. 25), unidentified serine proteases26 
and kinases27–33, such as PKC-δ, PKR, Syk, Lyn, PI(3)K, Erk and DAPK, in the 
activation or regulation of inflammasomes, but how these molecules participate in 
inflammasome activity remains largely unclear. 
Given the importance of the protective and pathological roles of inflammasomes, it is 
worth clarifying what and how signaling factors are involved in the activation of 
inflammasomes. Here we found that the NLRP3 and AIM2 inflammasomes, but not the 
NLRC4 inflammasome, required Syk and Jnk for their full activity. Inhibition of Syk or 
Jnk abolished the NLRP3- or AIM2-mediated formation of ASC specks without affecting 
the interaction between ASC and NLRP3. We also found that ASC underwent Syk- and 
Jnk-dependent phosphorylation and that Tyr144, one of the possible phosphorylation 
sites, was critical for speck formation. Our results indicate the phosphorylation of ASC 




NLRP3 and AIM2 require Syk and Jnk for IL-18 secretion 
To examine the role of kinases in inflammasome activation, we assessed the effects of  
a series of common kinase inhibitors (Supplementary Table 1) on the NLRP3, AIM2 and 
NLRC4 inflammasomes in peritoneal macrophages. To rule out the possibility of effects 
of the inhibitors on signal 1 delivered by priming with lipopolysaccharide (LPS), we 
added the inhibitors to macrophage cultures 3 h after the initiation of LPS priming. 
Those inhibitors did not affect the abundance of the inflammasome components or of 
pro-IL-18 or pro-IL-1β at the protein level (Supplementary Fig. 1a). We measured IL-18 
secretion as an indicator of caspase-1 activation, as pro-IL-18, unlike pro-IL-1β, is 
constitutively expressed in macrophages31. The nigericin-induced secretion of IL-18  
from macrophages was significantly lower after pretreatment with an inhibitor of Syk 
or Jnk, but not after pretreatment with inhibitors of other kinases, than after 
pretreatment with dimethyl sulfoxide, as a control (Fig. 1a). We obtained similar results 
with mouse bone marrow–derived macrophages and the U937 human macrophage cell 
line (Supplementary Fig. 1b,c), which excluded the possibility of macrophage type– and 
species-specific effects. The production of IL-18 induced by alum, another NLRP3 
activator, was also diminished by pretreatment with an inhibitor of Syk or Jnk 
(Supplementary Fig. 1e), which suggested that Syk and Jnk contributed to activation of 
the NLRP3 inflammasome. Moreover, we found that the production of IL-18 induced by 
the synthetic B-form double-stranded DNA poly(dA:dT), but not that induced by 
flagellin, was substantially inhibited by pretreatment with an inhibitor of Syk or Jnk 
(Fig. 1b,c). To confirm the role of Syk and Jnk in this, we used small interfering RNA to 
knock down the expression of Syk or the genes encoding Jnk1 and Jnk2 (Mapk8-Mapk9) 
in macrophages, and also assessed macrophages with knockout of Syk, Mapk8 or 
Mapk9, and found that either knockdown or knockout decreased the secretion of IL-18 
in response to nigericin or poly(dA:dT) (Fig. 1d–h and Supplementary Fig. 2a–d). Also, 
the nigericin-induced secretion of IL-1β from macrophages was reduced by an inhibitor 
of Syk or Jnk or knockout of either Syk or Mapk8-Mapk9 (Fig. 1e and Supplementary 
Fig. 1d). Those observations suggested involvement of Syk and Jnk in activation of the 
NLRP3 and AIM2 inflammasomes. Syk deficiency in macrophages resulted in a 
moderate decrease in the secretion of IL-18 and IL-1β induced by nigericin (Fig. 1d,e), 
which indicated that Syk was not a critical requirement for activation of the NLRP3 
inflammasome but instead contributed to that. Salmonella enterica serovar 
Typhimurium 14028 (S. Typhimurium) and Mycobacterium tuberculosis strain H37Rv 
are recognized mainly by NLRC4 and NLRP3, respectively, while Listeria 
monocytogenes strain EGD is recognized by various receptors, including AIM2 and 
NLRP3 (refs. 6,17,33). Consistent with the results reported above obtained by 
stimulation by ligands, IL-18 production induced by S. Typhimurium was not affected 
much by inhibition of Syk or Jnk in macrophages, whereas IL-18 production induced by 
M. tuberculosis or L. monocytogenes was reduced by inhibition of Syk or Jnk (Fig. 1i–k). 
From these results, we concluded that Syk and Jnk contributed to the activity of the 
NLRP3 and AIM2 inflammasomes but not that of the NLRC4 inflammasome. 
 
Caspase-1 activation requires Syk and Jnk 
Next we assessed the involvement of Syk and Jnk in the activation of caspase-1 via the 
NLRP3 and AIM2 inflammasomes. Activation of caspase-1 induced by nigericin, alum 
or poly(dA:dT) in peritoneal macrophages was almost completely abolished in the 
presence of an inhibitor of Syk or Jnk but not in the presence of inhibitors of other 
kinases (Fig. 2a,b and Supplementary Fig. 1f). In contrast, we did not observe effects of 
those two inhibitors on the activation of caspase-1 induced by flagellin or S. 
Typhimurium (Fig. 2c,d). Furthermore, activation of caspase-1 induced by nigericin or 
poly(dA:dT) was reduced in Syk- or Jnk-deficient macrophages and by knockdown of 
those kinases mediated by small interfering RNA (Fig. 2e–h and Supplementary Fig. 
2e,f). The activation of caspase-1 induced by M. tuberculosis or L. monocytogenes in 
macrophages was lower after treatment with an inhibitor Syk or Jnk than after 
treatment with the dimethyl sulfoxide control (data not shown). These results suggested 
that Syk and Jnk signals were involved in the activation of caspase-1 through the 
NLRP3 and AIM2 inflammasomes but not in the NLRC4 inflammasome–dependent 
activation of caspase-1. 
 
Syk is not required for NLRP3 inflammasome in dendritic cells 
It has been reported that Syk is not required for nigericin-induced activation of the 
NLRP3 inflammasome in dendritic cells28. Consistent with that report, we observed no 
significant difference between wild-type and Syk-deficient bone marrow–derived 
dendritic cells in caspase-1 activation or IL-18 secretion in response to nigericin 
(Supplementary Fig. 3a,c,d). In contrast, IL-18 secretion and caspase-1 activation 
induced by nigericin were lower in Syk-deficient peritoneal macrophages and bone 
marrow–derived macrophages than in Syk+/+ or Syk+/− cells (Figs. 1d,e and 2e and 
Supplementary Fig. 3b,e). This suggested that the requirement for Syk in NLRP3 
activation in response to nigericin was cell type specific. 
 
Syk and Jnk regulate inflammasomes via unknown pathways 
We investigated whether inflammasome-activating agents induced activation of Syk 
and Jnk, assessed by the detection of phosphorylated kinases. Stimulation with 
nigericin or poly(dA:dT) induced detectable levels of phosphorylated Syk and Jnk 
(Supplementary Fig. 4a–d). The phosphorylation of Jnk induced by nigericin or 
poly(dA:dT) was not reduced by inhibitors of Syk or in Syk-deficient peritoneal 
macrophages (Supplementary Fig. 4e–g), which suggested that Syk is not upstream of 
Jnk in this process. Syk is reported to serve a pivotal role in activation of the NLRP3 
inflammasome in response to Candida albicans by inducing the generation of reactive 
oxygen species (ROS) and CARD9-dependent activation of the transcription factor 
NF-κB28. However, we observed that wild-type and CARD9-deficient macrophages 
produced similar levels of IL-18 in response to nigericin or poly(dA:dT) and that the 
ROS scavenger BHA did not affect activation of the AIM2 inflammasome in 
macrophages (Supplementary Fig. 4h–j). Moreover, the expression of mitochondrial 
ROS, which is important for the activation of NLRP3, was not reduced by an inhibitor of 
Syk or Jnk in nigericin-stimulated macrophages (Supplementary Fig. 4k). These results 
indicated that Syk- and Jnk-dependent activation of the inflammasome is not mediated 
by ROS or CARD9 and that Syk and Jnk operate in a different pathway(s). 
 
The formation of ASC specks requires Syk and Jnk 
Both NLRP3 and AIM2 require the common adaptor ASC to recruit and activate 
pro-caspase-1 (ref. 1). We therefore speculated that Syk and Jnk might be involved in 
the interaction of ASC with NLRP3 or AIM2. To investigate that possibility, we 
visualized ASC-NLRP3 complexes by an in situ proximity ligation assay (PLA). As 
reported before30, we observed small spots of ASC-NLRP3 complexes in peritoneal 
macrophages, and these increased in abundance after stimulation with nigericin (Fig. 
3a). The abundance of spots was not increased by stimulation with nigericin in the 
absence of ASC or NLRP3 (data not shown), which suggested that ASC-NLRP3 
complexes were specifically visualized by this technique. After stimulation with 
nigericin, the number of spots representing ASC-NLRP3 complexes was similar in 
macrophages pretreated with an inhibitor of Syk or Jnk and those pretreated with 
dimethyl sulfoxide (Fig. 3a,b), which indicated that inhibition of Syk or Jnk did not 
affect the interaction between NLRP3 and ASC, a critical step in formation of the 
NLRP3 inflammasome, in macrophages stimulated with nigericin. Next we visualized 
the formation of ASC specks and found that pretreatment with an inhibitor of Syk or 
Jnk or deficiency in either Syk or Jnk reduced the nigericin-induced formation of ASC 
specks in macrophages (Fig. 3c–f and Supplementary Fig. 5a,b). Because ASC has been 
reported to form Triton X-100–resistant aggregates20, we prepared Triton X-100–soluble 
and Triton X-100–insoluble fractions from macrophages to analyze the distribution of 
ASC. ASC was almost undetectable in the Triton X-100–insoluble fraction of 
LPS-primed macrophages but was significantly greater in abundance after stimulation 
with nigericin (Fig. 3g). Moreover, most ASC in the Triton X-100–insoluble fraction was 
a dimer or oligomer15 (Fig. 3h). Pretreatment with an inhibitor of Syk or Jnk reduced 
the redistribution of ASC induced by nigericin and also resulted in a decrease in the 
amount of dimerized and oligomerized ASC (Fig. 3g,h). We obtained similar results for 
macrophages stimulated with poly(dA:dT) (Fig. 3i,j and Supplementary Fig. 5c–f). 
These results suggested that signaling by Syk and Jnk was required for the formation of 
ASC specks but not for the NLR-ASC interaction. 
 
Phosphorylation of ASC after inflammasome activation 
A published report has implied that ASC undergoes phosphorylation in response to 
inflammatory stimuli34. To investigate whether the aggregate formation of ASC was 
regulated by its phosphorylation mediated by Syk and Jnk during inflammasome 
activation, we enriched phosphorylated proteins from macrophage lysates through the 
use of a column containing a phosphorylated protein–binding resin and then detected 
ASC by immunoblot analysis. We observed that stimulation with nigericin induced an 
increase in the amount of ASC in the elution fraction (with enrichment for 
phosphorylated proteins; Fig. 4a). To further analyze the phosphorylation of ASC, we 
obtained Triton X-100–soluble and Triton X-100–insoluble cell lysates and analyzed 
them by a mobility-shift assay (MSA) based on the phosphate-binding tag Phos-tag35. In 
these gels, ASC in the Triton X-100–insoluble fraction migrated more slowly than that 
in the Triton X-100–soluble fraction, and the shift in mobility was reversed by 
phosphatase treatment (Fig. 4b,c), which suggested that ASC in the former fraction was 
phosphorylated. We observed the slowly migrating ASC in the Triton X-100–insoluble 
fraction of caspase-1-deficient macrophages but not in that of NLRP3-deficient 
macrophages, after stimulation with nigericin (Fig. 4b), which suggested that the 
increase in phosphorylated ASC in response to nigericin required NLRP3 but not 
caspase-1. ASC may be phosphorylated at multiple sites, as we detected three major 
bands with different mobility (Fig. 4c–g). In addition, deficiency in either Syk or Jnk 
decreased the intensity of the ASC band with the lowest mobility in the Triton 
X-100–insoluble fraction of macrophages stimulated with nigericin or poly(dA:dT) (Fig. 
4d–g). We obtained similar results with an inhibitor of Syk or Jnk (data not shown). 
These data suggested that ASC was phosphorylated after activation of the NLRP3 and 
AIM2 inflammasomes via the Syk and Jnk pathways. Syk and DAPK have been shown 
to associate with the NLRP3 inflammasome complex29,30. Accordingly, we analyzed the 
interaction of ASC with phosphorylated Jnk by in situ PLA. We observed complexes of 
ASC with phosphorylated Jnk in wild-type macrophages (Fig. 4h–k), but not in 
ASC-deficient macrophages (negative control; data not shown), after stimulation with 
nigericin or poly(dA:dT). Notably, most of the complexes were located in or around the 
nucleus at later time points (Fig. 4h,j). These data suggested that ASC was 
phosphorylated after activation of the NLRP3 and AIM2 inflammasomes via the Syk 
and Jnk pathways. 
 
Phosphorylation of ASC is critical for inflammasome activation 
We next sought to identify ASC-phosphorylation sites that regulate the aggregate 
formation that results in activation of caspase-1. We detected 14 or 8 possible 
phosphorylation sites, respectively, in mouse ASC with NetPhos (a neural 
network–based method for predicting potential phosphorylation sites at serine, 
threonine or tyrosine residues; version 2.0), at a threshold of 0.5, or with GPS (a 
group-based prediction system for the computational prediction of phosphorylation sites 
with their cognate kinases; version 2.1.1) with the low threshold (Supplementary Fig. 6 
and Supplementary Table 2). We constructed a series of expression vectors encoding 
ASC mutants in which amino acid residues predicted to be phosphorylated were 
replaced  with alanine or phenylalanine, then assessed the ability of those ASC point 
mutants to induce IL-1β secretion in an inflammasome-reconstitution system based on  
HEK293 human embryonic kidney cells (Supplementary Fig. 7a,b). We observed that  
the ability of the point mutants ASC(S58A), ASC(T125A), ASC(Y144F) or 
ASC(T151A,T152A,S153A) to induce IL-1β secretion in response to NLRP3(R258W), a 
disease-associated mutant of NLRP3, was slightly lower that of wild-type ASC (Fig.  
5a,b). We further altered the ASC(S58A) mutant by the additional substitution T125A 
or with the three additional substitutions of T151A, T152A and S153A 
(ASC(58,151–153)) and found that IL-1β-inducing ability of the resulting ASC mutants 
was significantly lower than that of ASC(S58A) (Fig. 5b). Furthermore, ASC(Y144F) 
and ASC(58,151–153) showed less redistribution into the Triton X-100–insoluble 
fraction in response to NLRP3(R258W) than did wild-type ASC (Fig. 5c,d). ASC(Y144F) 
and ASC(58,151–153) were still able to form dimers and oligomers in the Triton 
X-100–insoluble fraction (Fig. 5e), probably because those substitutions affected the 
redistribution of ASC without affecting its dimerization or oligomerization. Moreover, 
we found that ASC(Y144F) expressed together with NLRP3(R258W) formed almost no 
aggregates, in contrast to wild-type ASC expressed together with NLRP3(R258W) (Fig. 
5f). These results suggested that Tyr144, Ser58, Thr151, Thr152 and Ser153, all 
putative phosphorylation sites of ASC, were involved in both IL-1β-inducing ability and 
aggregate formation. 
We investigated whether those results obtained with HEK293 cell could be 
reproduced in the mouse macrophage cell line RAW264.7, which lacks ASC expression. 
Wild-type ASC expressed together with NLRP3(R258W) in RAW264.7 cells formed 
speck-like structures and induced the activation of caspase-1, whereas speck formation 
was diminished in RAW264.7 cells transfected to express ASC(Y144F) or 
ASC(58,151–153) (Fig. 6a–c). The formation of ASC specks was also abrogated by the 
substitutions in similar experiments with ASC deficient primary macrophages (Fig. 6d). 
We further investigated whether those residues were phosphorylated in a Syk- and 
Jnk-dependent manner. ASC expressed together with either Syk or Jnk migrated more 
slowly in Phos-tag gels than did ASC in cells transfected with empty vector (Fig. 7a). 
Transfection of cells to express ASC with both Syk and Jnk resulted in a greater 
mobility shift, which was reversed by phosphatase treatment (Fig. 7a,b). These results 
suggested that ASC was phosphorylated at multiple sites in a Syk- and Jnk-dependent 
manner. The observed changes in the mobility of ASC in the presence of Syk or Jnk were 
all abrogated by the Y144F substitution in ASC (Fig. 7c). In contrast, the mobility of 
ASC(S58A),  ASC(T151A,T152A,S153A) and ASC(58,151–153) in Phos-tag gels, like 
that of wild-type ASC, was reduced by overexpression of Jnk1-Jnk2 (Fig. 7d), which 
suggested that Ser58, Thr151, Thr152 and Ser153 were not phosphorylated in a 
Jnk-dependent manner or that the effect of those substitutions on the mobility may 
have been masked by phosphorylation at other residues. These results showed that 
phosphorylation of Tyr144 was required for inflammasome activation. 
We did in vitro kinase assays with synthetic peptides (amino acids 139–150 of mouse 
ASC or amino acids 141–152 of human ASC) to investigate the possibility that Syk 
directly phosphorylates Tyr144 of mouse ASC and the corresponding tyrosine residue of 
human ASC. We incubated those peptides with ATP in the presence or absence of 
recombinant Syk and assessed the kinase reaction by the consumption of ATP. We did 
not observe substantially less ATP in reactions in which we used those ASC peptides as 
a substrate for recombinant Syk, whereas reactions containing purified tubulin, as a 
positive control substrate, had less ATP (data not show). Thus, our data did not support 
or were not sufficient to justify the possibility of direct phosphorylation of Tyr144 by 
Syk. 
 MSU- and alum-induced peritonitis is dependent on Syk and Jnk 
Next we investigated whether Syk and Jnk were required for inflammasome activation 
in vivo. We analyzed the recruitment of inflammatory cells into the peritoneal cavity as 
an indicator of stimulant-induced inflammation after intraperitoneal injection of mice 
with MSU or alum. As shown before12,29, both MSU and alum strongly induced the 
recruitment of cells, including Gr-1+ F4/80− neutrophils and F4/80+ monocytes and 
macrophages, in an ASC dependent manner (Supplementary Fig. 8a–f). We then 
reconstituted irradiated wild-type mice with fetal liver cells to generate Syk+/− and 
Syk−/− chimeras or with bone marrow cells to generate wild-type, Mapk8−/− and 
Mapk9−/− chimeras. After challenge with MSU or alum, Syk−/− chimeras had fewer total 
cells, neutrophils, and monocytes-macrophages in the peritoneal cavity than did Syk+/− 
chimeras (Fig. 8a,b,d–f). After challenge with MSU, the number of peritoneal 
monocytes-macrophages tended to be lower in Syk−/− chimeras than in Syk+/− chimeras, 
but the difference between the groups was not statistically significant (Fig. 8c). The 
infiltration of inflammatory cells induced by MSU or alum was also lower in Mapk8−/− 
chimeras or in wild-type mice treated with an inhibitor of Jnk than in wild-type 
chimeras or wild-type mice treated with vehicle only, respectively (Fig. 8g–i and 
Supplementary Fig. 8a–f). In contrast, the inflammasome-independent infiltration of 
inflammatory cells induced by chemokine CXCL1 (KC) was similar in Syk+/− and Syk−/− 
chimeras and in Mapk8+/+ and Mapk8−/− chimeras (Supplementary Fig. 8g–l), and the 
inhibitor of Jnk did not reduce the infiltration of inflammatory cells induced by alum in 
ASC-deficient mice (n= 3; data not shown). These results suggested that signaling via 
Syk and Jnk was involved in the MSU- and alum-induced infiltration of inflammatory 






The phosphorylation and dephosphorylation of proteins is important in controlling a 
wide range of biological processes, including innate and adaptive immunity and 
apoptosis36,37. The involvement of kinases such as PKC-δ, PKR, Syk, Lyn, PI(3)K, Erk 
and DAPK in inflammasome activation has been reported, yet the precise mechanism of 
their action has remained unclear. In particular, Syk has been demonstrated to 
contribute to the NLRP3 inflammasome in response to C. albicans, most probably due to 
its role in inducing ROS production28,29,31,33. NLRC4 is phosphorylated after stimulation 
with its ligands, and that phosphorylation is critical for inflammasome activation27. 
Here we showed that Syk and Jnk were involved in the activity of ASC-containing 
inflammasomes in macrophages via a mechanism that regulated the formation of ASC 
specks. We found that ASC was phosphorylated in a Syk- and Jnk-dependent manner at 
multiple sites, which most probably included Tyr144, which was essential for speck 
formation. The phosphorylation of ASC during inflammasome activation was required 
for activity of the NLRP3 and AIM2 inflammasomes. Thus, inflammasomes are 
regulated by protein kinases and perhaps by phosphatase(s) that target phosphorylated 
inflammasome components. 
We identified Tyr144 of ASC as a critical residue for speck formation and a possible 
phosphorylation site. Consistent with that, phosphorylation of the corresponding 
residue in human ASC (Tyr146) has been disclosed in a patent application (Hornbeck, P. 
et al., US patent application 2009/0325189 A1). The Y144F substitution in ASC 
completely abrogated the phosphorylation of ASC induced by overexpression of Syk or 
Jnk, which suggested that Tyr144 serves as a regulator of ASC phosphorylation 
mediated by those kinases. That tyrosine residue is evolutionary conserved. Tyr144 is 
located in the CARD, whereas published studies have shown that the pyrin domain of 
ASC is phosphorylated after stimulation with tumor-necrosis factor34, which suggests 
the existence of other phosphorylation sites that might also contribute to inflammasome 
activity. 
It remains unclear how signaling via Syk and Jnk regulates the formation of ASC 
specks. Transfection of HEK293 cells to express ASC together with Syk or Jnk or both 
did not result in the formation of ASC specks or the redistribution of ASC to the Triton 
X-100–insoluble fraction (data not shown), which suggested that phosphorylation of 
ASC itself was not sufficient to induce speck formation in the absence of stimuli of the 
inflammasome. Our results also suggested a crucial role for Syk and Jnk in the 
redistribution, rather than the dimerization or oligomerization, of ASC upon 
inflammasome activation. During the generation of ASC aggregates, monomeric ASC, 
which is diffusely distributed before stimulation, is rapidly translocated to a perinuclear 
speck in each cell. The formation of ASC specks is prevented by treatment with 
nocodazole, and ASC specks are located near the microtubule-organizing center38, which 
suggests a possible role for microtubules in the migration of ASC during the step of 
speck formation. In our assays, most complexes of ASC and phosphorylated Jnk were 
located in or around the nucleus, and ASC remained diffusely distributed in the cytosol 
even after inflammasome activation in cells in which Syk or Jnk was inhibited 
genetically or pharmacologically. Thus, we speculate that Syk- and Jnk-mediated ASC 
phosphorylation may function as a molecular ‘switch’ that controls the migration of ASC 
along microtubules to the site of speck formation. Together, these results indicate that 
ASC speck formation is a consequence of multiple cellular events orchestrated by 
inflammasome receptors, Syk, Jnk and perhaps microtubules. 
Although inflammasomes have pivotal roles in innate immunity to pathogens, 
excessive or dysregulated activation of inflammasomes, especially the NLRP3  
inflammasome, has been linked to various autoinflammatory diseases and  
autoimmune diseases, including Muckle-Wells syndrome, inflammatory bowel 
diseases39,40, vitiligo41 and rheumatoid arthritis12. Inflammasomes have also been 
linked to obesity-induced insulin resistance42, atherosclerosis43 and gouty arthritis44 
and could represent potential targets for therapy. Therapies involving antibody to IL-1β 
appear to be effective in treating inflammatory disorders associated with deregulated 
inflammasome activity, and further understanding of the basic processes and 
mechanisms involved in inflammasome activation will provide additional strategies for 
controlling autoinflammatory conditions. Here we have shown that phosphorylation of 
the inflammasome component ASC regulates inflammasome activity. Thus, for example, 
compounds designated to specifically inhibit the phosphorylation of ASC may be 
promising drug candidates for the treatment of inflammasome-associated diseases, and 
antibodies specific to phosphorylated ASC may be useful for diagnostic and research 
purposes. Further investigation of the inflammasome will reveal the precise roles of 
kinases in inflammasome activation and may identify additional mechanisms for 
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Figure 1 Syk and Jnk are required for IL-18 secretion mediated by NLRP3 and AIM2 
but not that mediated by NLRC4. Enzyme-linked immunosorbent assay of IL-18 
(a–d,f–k) and IL-1β (e) in peritoneal macrophages primed for 4 h with LPS, followed by 
stimulation for 90 min with nigericin (a,d,e,g) or for 6 h with encapsulated flagellin (c) 
or infection for 6 h with S. Typhimurium (i) or in unprimed macrophages stimulated for 
3 h with poly(dA:dT) (b,f,h) or infected for 24 h with M. tuberculosis (j) or L. 
monocytogenes (k), without inhibitors (d–h) or with addition of the Syk inhibitors R406 
(1 µM), Syk inhibitor I (SI; 1 µM) and BAY 61-3606 (BAY; 10 µM), the Src inhibitor PP2 
(5 µM), the Jnk inhibitors SP600125 (SP; 40 µM) and TAT-TI-JIP153–163 (TAT; 40 µM), 
the p38 inhibitor SB203580 (SB; 10 µM), the Erk inhibitor FR180204 (FR; 10 µM) and 
the PI(3)K inhibitor wortmannin (WO; 10 nM) (horizontal axes) to the cultures 1 h 
before stimulation or infection for inflammasome activation (a–c,i–k). Expt, experiment. 
*P< 0.01 and **P< 0.001 (one-way analysis of variance (ANOVA) with Bonferroni’s 
multiple-comparison test (a–c,g–k) or two-tailed unpaired t-test with Welch’s correction 
(d–f)). Data are representative of at least three independent experiments (a–f,i–k) or 
two independent experiments (g,h; mean and s.d. of triplicates). 
 
Figure 2 Involvement of Syk and Jnk in NLRP3- and AIM2-mediated activation of 
caspase-1. Immunoblot analysis of inflammasome molecules in peritoneal macrophages 
primed for 4 h with LPS, followed by stimulation for 90 min with nigericin (a,e,g) or for 
6 h with encapsulated flagellin (c) or S. Typhimurium (d) or in unprimed macrophages 
stimulated for 3 h with poly(dA:dT) (b,f,h), without inhibitors (e–h) or with the addition 
of kinase inhibitors (above lanes) to the cultures 1 h before stimulation (a–d). Casp1, 
caspase-1 (p10, subunit; p45, precursor); CL, cell lysate; SN, supernatant. Data are 
representative of at least three independent experiments (a–f) or two independent 
experiments (g,h). 
 
Figure 3 Requirement for signaling via Syk and Jnk for ASC aggregation. (a–h) In situ 
PLA of ASC-NLRP3 complexes (a,b), ASC staining (c–f) and immunoblot analysis of 
ASC (g,h) in peritoneal macrophages primed for 4 h with LPS, followed by stimulation 
for various times (above) with nigericin in the presence or absence of kinase inhibitors. 
(a,c) ASC-NLRP3 complexes, red (a); ASC, green (c); nuclei, blue (a,c). Scale bars, 10 µm. 
(b) Quantification of PLA signals per cell, presented relative to that of control cells 
treated with solvent. (d–f) Quantification of cells with ASC specks, presented relative to 
that of control cells treated with solvent or wild-type cells. (g,h) Triton-soluble (S) and 
Triton-insoluble (I) fractions (right margin; g) or Triton-insoluble fractions treated with 
disuccinimidyl suberate (I + DSS; h). (i,j) ASC staining in unprimed macrophages 
stimulated for 3 h with poly(dA:dT), presented as in d–f. *P< 0.001 (Kruskal-Wallis test 
with Dunn’s multiple-comparison test (b,j), one-way ANOVA with Bonferroni’s 
multiple-comparison test (d,f), two-tailed unpaired t-test with Welch’s correction (e) or 
Mann-Whitney test (i)). Data are representative of at least three independent 
experiments (a–d,g,h) or two independent experiments (e,f,i,j; mean and s.d. of 
triplicates in b,d–f,i,j). 
 
Figure 4 Phosphorylation of ASC in macrophages after activation of the inflammasome. 
(a) Enrichment and immunoblot analysis (IB) of phosphorylated ASC in original cell 
lysates (Lys) and the elution (Elution) and flow-through (Flow) fractions of peritoneal 
macrophages primed for 4 h with LPS, followed by no stimulation (−) or stimulation (+) 
for 60 min with nigericin and then fractionation through a column containing a resin 
that binds phosphorylated proteins. α-ASC, antibody to ASC; α-p-Tyr, antibody to 
phosphorylated tyrosine. (b–g) Phos-tag MSA of phosphorylated (p-) and total ASC in 
Triton-soluble and Triton-insoluble fractions of peritoneal macrophages primed for 4 h 
with LPS, followed by no stimulation or stimulation for 60 min with nigericin (b–e), or of 
unprimed macrophages stimulated for 2 h with poly(dA:dT) (f,g), analyzed by 
SDS-PAGE with (+) or without (−) Phos-tag (left margin); filled triangles indicate three 
major bands with different mobility. Fractions were dissolved in 300 µl (S) or 50 µl (I) 
SDS sample buffer (b,d–g). (h–k) In situ PLA of peritoneal macrophages primed for 4 h 
with LPS, followed by stimulation for 0–60 min with nigericin (h,i) or of unprimed 
macrophages stimulated for 0–2 h with poly(dA:dT) (j,k). (h,j) Red, complexes of ASC 
with phosphorylated Jnk (ASC + p-Jnk); blue, nuclei. Scale bars, 10 µm. (i,k) Results 
presented relative to those of unstimulated control cells. *P< 0.01 and **P< 0.001 
(Kruskal-Wallis test with Dunn’s multiple-comparison test (i) or one-way ANOVA with 
Tukey-Kramer multiple-comparison test (k)). Data are representative of two (a,c,e–g) or 
three (b,d,h–k) independent experiments (mean and s.d. of triplicates in i,k). 
 
Figure 5 Identification of amino acid residues in ASC critical for its biological activities. 
(a,b) Enzyme-linked immunosorbent assay of IL-1β in HEK293 cells 48 h after 
reconstitution by transfection of empty vector (EV) or vector encoding Flag-tagged 
NLRP3(R258W) (100 ng) (key) along with empty vector or vector encoding Flag-tagged 
wild-type (WT) or mutant ASC (10 ng; horizontal axes), plus vector encoding 
pro-caspase-1 (30 ng) and pro-IL-1β (100 ng). 58,125, ASC(S58A) with the additional 
substitution T125A. (c–e) Immunoblot analysis (c,e) and quantification (d) of ASC in 
Triton-soluble and Triton-insoluble fractions (c,d) and disuccinimidyl suberate–treated 
Triton-insoluble fractions (e) of reconstituted HEK293 cells 48 h after transfection of 
empty vector or vector encoding Flag-tagged NLRP3(R258W) (left margin (c), top (d) or 
above lanes (e)) along with vector encoding Flag-tagged wild-type or mutant ASC (left 
margin (c), horizontal axis (d) or above lanes (e)); in d, band intensity of insoluble ASC is 
presented relative to that of soluble ASC. (f) ASC staining in HEK293 cells treated as in 
c–e: red, ASC; green, transfected cells (visualized by transfection of a plasmid encoding 
green fluorescent protein (100 ng)). Scale bars, 10 µm. *P< 0.05 and **P< 0.001 
(one-way ANOVA with Bonferroni’s multiplecomparison test (a,b) or Tukey-Kramer’s 
multiple-comparison test (d)). Data are from one experiment representative of three 
independent experiments (mean and s.d. of triplicates in a,b,d). 
 
Figure 6 Critical roles of the possible phosphorylation sites of ASC in macrophages. 
(a–c) Immunoblot analysis of inflammasome molecules (a), ASC staining (b) and 
quantification of ASC specks (c) in reconstituted RAW264.7 cells 9 h after transfection of 
vector encoding Flag-tagged NLRP3(R258W) plus empty vector or vector encoding 
wild-type or mutant ASC (above lanes or images (a,b) or horizontal axis (c)). (b) ASC, 
green; nuclei, blue. Scale bars, 10 µm. (c) Results presented relative to those of the cells 
transfected with empty vector. (d) Quantification of ASC specks in primary Pycard−/− 
peritoneal macrophages 9 h after reconstitution by transfection of vector encoding 
Flag-tagged NLRP3(R258W) plus empty vector or vector encoding Flag-tagged ASC 
(presented as in c). ND, not detected. *P< 0.001 (one-way ANOVA with Bonferroni’s 
multiplecomparison test (c,d)). Data are from one experiment representative of three 
independent experiments (mean and s.d. of triplicates in c,d). 
 
Figure 7 Identification of phosphorylation sites in ASC. (a) Phos-tag MSA of 
reconstituted HEK293 cells 48 h after transfection of vector encoding Flag-tagged 
wild-type ASC (50 ng) plus empty vector or vector encoding Syk (300 ng) (S) or Jnk1 
(300 ng) and Jnk2 (300 ng) (J) or vectors encoding Syk, Jnk1 and Jnk2 (S+J). (b) 
Phos-tag MSA of reconstituted HEK293 cells 48 h after transfection of vector encoding 
Flag-tagged wild-type ASC plus empty vector or vectors encoding Syk, Jnk1 and Jnk2, 
followed by no treatment (−) or treatment with phosphatase (+). (c) Phostag MSA of 
reconstituted HEK293 cells 48 h after transfection of vector encoding Flag-tagged 
ASC(Y144F) plus vectors as in a(above lanes). (d) Phos-tag MSA of reconstituted 
HEK293 cells 48 h after transfection of vector encoding Flag-tagged wild-type or mutant 
ASC (top) plus empty vector (−) or vector Jnk1 (300 ng) and Jnk2 (300 ng) (+). Data are 
representative of three independent experiments. 
 
Figure 8 Involvement of Syk and Jnk in inflammatory responses to MSU in vivo. (a–i) 
Absolute number of peritoneal exudate cells (PECs) (a,d,g), Gr-1+F4/80− neutrophils 
(b,e,h) and F4/80+ monocytes-macrophages (c,f,i) in the peritoneum of chimeras 
(identified (horizontal axes) by cells used for reconstitution) 6 h after intraperitoneal 
injection of MSU (a–c,g–i) or alum (d–f). Each symbol represents an individual mouse 
(n= 5 per group); small horizontal lines indicate the mean (±s.d.). *P< 0.05 and **P< 
0.01 (two-tailed unpaired Mann-Whitney test (a,c), two-tailed unpaired t-test with 
Welch’s correction (b,d–f), one-way ANOVA with Bonferroni multiple comparison test (g) 
or Kruskal-Wallis test with Dunn’s multiple comparison test (h,i)). Data are 






Mice. Female wild-type, Casp1−/−, Pycard−/−, Nlrp3−/−, Card9−/−, Mapk8−/− and Mapk9−/− 
C57BL/6J mice were maintained in specific pathogen–free conditions and were used at 
6–9 weeks of age12,16,45,46. C57BL/6J mice heterozygous for the Syktm1Tyb allele47 were 
intercrossed to generate embryos at embryonic day 16.5 that were wild-type for 
Syk(Syk+/+) or heterozygous or homozygous for the Syktm1Tyb allele (Syk+/− or Syk−/−). 
Fetal liver cells from those embryos were used to reconstitute C57BL/6J mice that had 
been irradiated with a total dose of 10 Gy from a 137Cs source. Bone marrow cells from 
wild-type, Mapk8−/− or Mapk9−/− mice were also used to reconstitute irradiated 
C57BL/6J mice. Mice were used 6–7 weeks after reconstitution. All the experimental 
procedures performed on mice were approved by the Animal Ethics and Research 
Committee of Kyoto University Graduate School of Medicine. 
 
Cells. Peritoneal macrophages, bone marrow–derived macrophages and bone 
marrow–derived dendritic cells were prepared as reported48,49. Those cells suspended in 
culture medium consisted of RPMI-1640 medium supplemented with 10% FCS and 10 
µg/ml gentamicin were incubated on culture plates overnight at 37 °C, then were used 
for this study. U937 cells (provided by M. Matsuura) were cultured for 3 d in culture 
medium supplemented with 10 ng/ml of 12-O-tetradecanoylphorbol 13-acetate, 100 
U/ml of penicillin and 100 µg/ml of streptomycin. The order of treatment and positions 
of wells in multiwell devices were determined randomly. 
 
Reagents. LPS and flagellin were from Invivogen; alum was from Pierce; nigericin and 
poly(dA:dT) were from Sigma-Aldrich; MSU was from Nacalai Tesque; R406 was from 
Selleckchem; other kinase inhibitors were from Merck Biosciences; and BHA (butylated 
hydroxyanisole) was from Wako. Polyclonal antibody to ASC (AL177) and mouse 
monoclonal antibody (mAb) to NLRP3 (Cryo-2) were from Alexis; mAb to Jnk (56G8), 
mAb to phosphorylated Jnk (81E11) and mouse mAb to phosphorylated Jnk (G9) were 
from Cell Signaling Technology; mAb to phosphorylated Tyr (PY20), antibody to 
caspase-1 p10 (M-20) and antibody to Syk (anti-Syk) (N-19) were from Santa Cruz; 
anti-Flag (600-401-383) was from Rockland Immunochemicals; biotin-conjugated 
anti-IL-1β (BAF401) was from R&D Systems; and mAb to IL-18 (39-3F) was from MBL. 
The enzyme-linked immunosorbent assay kit for mouse IL-1β was from eBioscience. For 
the ‘titration’ of human or mouse IL-18, a pair of biotin-labeled (93-10C) and unlabeled 
(74) monoclonal antibodies to IL-18 was used (both from MBL). 
 
Plasmids. The plasmid pmax-GFP was from Lonza. The pFLAG expression vectors for 
ASC, pro-caspase-1, and pro-IL-1β were constructed before16. The expression vectors for 
NLRP3 (R258W), Syk, Jnk1 (isoform β2) and Jnk2 (isoform β2) were constructed with 
primer sets (Supplementary Table 3) and the pFLAG-CMV2 vector (Sigma-Aldrich). 
After that construction, the mutation in the gene encoding NLRP3 or ASC was 
introduced into each expression vector by site-directed mutagenesis. Similarly, 
pFLAG–pro-caspase-1 and pFLAG–pro-IL-1β in which the Flag tag was removed were 
generated. 
 
Stimulation with inflammasome activators. Cells were plated at a density of 5 × 105 
cells per well in 24-well microplates. Culture medium was replaced with Opti-MEM 
(Invitrogen) before stimulation or infection. Macrophages were primed for 4 h with 50 
ng/ml LPS and stimulated with nigericin (5 µM) or alum (500 µg/ml). For delivery into 
the cytosol of macrophages, flagellin (15 ng) was encapsulated into Sendai virus 
envelope with GenomONE-Neo (Ishihara Sangyo). Poly(dA:dT) (2.6 µg/ml) was 
introduced into unprimed macrophages through the use of Lipofectamine LTX  
(Invitrogen). Cells were infected with L. monocytogenes EGD48 (multiplicity of infection, 
1) or S. Typhimurium 14028 (multiplicity of infection, 10), and gentamicin was added to 
the cultures 30 min after infection. Cells infected with M. tuberculosis H37Rv 
(multiplicity of infection, 5) were washed 3 h after infection and were further cultivated 
in Opti-MEM containing gentamicin. Kinase inhibitors or dimethyl sulfoxide were 
added to cell cultures 1 h before stimulation or infection for inflammasome activation. 
 
Immunoblot analysis. Cells were lysed with SDS sample buffer. Supernatants were 
concentrated with trichloroacetate. For the generation of Triton X-100–soluble and 
Triton X-100–insoluble fractions, cells were lysed with 50 mM Tris-HCl (pH 7.6) 
containing 0.5% Triton X-100, EDTA-free protease inhibitor ‘cocktail’ and phosphatase  
inhibitor ‘cocktail’ (Nacalai tesque). The lysates were centrifuged at 6,000g at 4 °C for 15 
min, and the pellets and supernatants were used as the Triton-insoluble and 
Triton-soluble fractions, respectively. For the detection of phosphorylated Syk, total Syk 
was immunoprecipitated with anti-Syk (N-19; Santa Cruz) and protein G Sepharose 
(GE Healthcare). 
 
Crosslinkage of ASC dimers or oligomers. The Triton-insoluble pellets were washed 
twice with Tris-buffered saline and then resuspended in 500 µl Tris-buffered saline. The 
resuspended pellets were crosslinked for 45 min at 37 °C with 2 mM disuccinimidyl 
suberate (Pierce) and then centrifuged for 15 min at 6,000g. The pellets were dissolved 
in SDS sample buffer. 
 
Enrichment of phosphorylated proteins. Phosphorylated proteins were enriched from 
cell lysates with a Pro-Q Diamond Phosphoprotein Enrichment Kit according to the 
manufacturer’s instructions (Invitrogen). Cells were lysed in lysis buffer supplemented 
with inhibitors of endonuclease and proteinase, then ASC aggregates were solubilized 
with 8 M urea. After centrifugation for 10 min at 10,000g, the supernatants were 
applied to the Pro-Q diamond column (1 mg protein per column). The column was 
washed and eluted with elution buffer (50 mM Tris, 2% SDS, 10 mM EDTA and 5% 
2-mercaptoethanol, pH 8). The flow-through and elution fractions were concentrated 
with trichloroacetate. ASC or phosphorylated tyrosine in each fraction was detected by 
immunoblot analysis. 
 
Phos-tag-based MSA. The Triton X-100–insoluble and Triton X-100–soluble fractions 
from macrophages (prepared as described above) were analyzed by Phos-tag MSA. 
HEK293 cells were lysed with 50 mM Tris-HCl (pH 7.6) containing 1% SDS, then 
lysates were precipitated with isopropanol and acetone. Proteins in the lysates were 
precipitated with acetone, incubated overnight at 37 °C in phosphatase reaction 
mixture containing 250 U/ml of antarctic phosphatase (New England BioLabs), 
reprecipitated with acetone and dissolved in SDS sample buffer. Those samples were 
separated by electrophoresis through 12% polyacrylamide gels with or without 50 µM 
MnCl2 and 25 µM Phos-tag ligand (NARD Institute). 
 
RNA-mediated interference. Cells were transfected with 30 nM small interfering RNA 
through the use of the siPORT Amine Transfection Agent (Ambion) as reported16. After 
48 h of cultivation, the cells were washed and used in experiments. The sense small 





UAAAGUUGGUACAGGCUGUUCGCGC; and Mapk9(B), 
UUCAAUCGCAUGCUCUCUUUCUUCC. Stealth RNAi negative control medium GC 
duplex #3 was from Invitrogen. 
 
Immunofluorescence staining. Cells seeded in eight-well chamber plates at a density of 
2.5 × 105 cells per well were washed twice, fixed in 4% paraformaldehyde and 
permeabilized with 0.25% Triton X-100. The cells were incubated with anti-ASC 
(AL177; Alexis) and then with Alexa 488-labeled or Alexa 594-labeled antibody to rabbit 
IgG (A11034 or A11012; Invitrogen). Nuclei were stained with DAPI 
(4,6-diamidino-2-phenylindole; Dojindo). 
 
In situ PLA. Fixed and permeabilized cells were incubated overnight at 4 °C with the 
following pairs of primary antibodies: rabbit anti-ASC (AL177; Alexis) together with 
mouse mAb to phosphorylated Jnk (G9; Cell Signaling) or mouse mAb to NLRP3 
(Cryo-2; Alexis). The cells were washed and allowed to react to a pair of proximity 
probes (Olink Bioscience). The rest of the in situ PLA protocol was performed according 
to the manufacturer’s instructions. The cells were examined by fluorescence microscopy 
(Olympus), and the Duolink Image Tool (Olink Bioscience) was used for quantitative 
analysis. 
 
Reconstruction of the inflammasome system in HEK293 cells. HEK293 cells (CRL-1573; 
American Type Culture Collection) were maintained in DMEM supplemented with 10% 
FCS, 6 mM l-glutamine, 1 mM sodium pyruvate and 5 µg/ml gentamicin as described16. 
For experiments, HEK293 cells were plated in 24-well microplates at a density of 2 × 
105 cells per well and incubated overnight. The cells were transfected with plasmids 
through the use of Transfectin according to the manufacturer’s instructions (Bio-Rad). 
The total amount of DNA was adjusted to a concentration of 1 µg per well with 
pFLAG-CMV2 empty vector. The cells were washed with culture medium 36 h after 
transfection and were further incubated for 12 h. 
 
Reconstruction in macrophages. RAW264.7 cells (provided by H. Tanizaki) or primary 
Pycard−/− peritoneal macrophages were transfected with 1,000 ng of pFLAG-ASC or the 
ASC mutant vectors together with pFLAG-NLRP3 (R258W) (250 ng) through the use of 
the Neon Transfection System according to the manufacturer’s instructions (Invitrogen). 
Electroporation parameters were as follows: pulse voltage, 1,680 V; pulse width, 20 ms; 
pulse number, 1; cell number, 1 × 106. The cells were incubated for 9 h. 
 
Peritonitis. Mice were challenged intraperitoneally with MSU (1 mg) or alum (0.4 mg). 
At 2 h before and 30 min after challenge with the irritants, wild-type mice were treated 
intraperitoneally with dimethyl sulfoxide or the Jnk inhibitor SP600125 (25 mg per kg 
body weight). The mice were killed 6 h after injection of the stimuli, and peritoneal 
cavities were lavaged with 5 ml PBS. Mice were given intraperitoneal injection of mouse 
CXCL1 (0.8 µg; BioLegend) or PBS, and peritoneal cells were collected 1.5 h after 
stimulation. Peritoneal cells were counted with a Countess (Invitrogen) and then were 
allowed to react to mAb to mouse CD16 (93; BioLegend). The cells were subsequently 
stained with fluorescein isothiocyanate–labeled mAb to Gr-1 (RB6-8C5; BioLegend) and 
phycoerythrin-labeled mAb to F4/80 (BM8; BioLegend) and were analyzed on a 
FACSCalibur (Becton Dickinson). Mice were prepared by H.H. and were randomly 
assigned to experimental groups. Another investigator (R.F.), who did the injections and 
flow cytometry, was ‘blinded’ to the identity of the groups. 
 
Statistical analysis. The sample size of in vivo and in vitro studies was chosen to be as 
small as possible but to allow the evaluation of distribution normality. For two-group 
comparisons by Gaussian distribution, a two-tailed unpaired t-test with Welch’s 
correction was used when the variances of the groups were judged to be equal by the F 
test. For two-group comparisons with non-Gaussian distribution, a Mann-Whitney test 
was used. Multigroup comparisons with Gaussian distribution, one-way ANOVA with 
Bonferroni’s multiple-comparison test or Tukey-Kramer’s multiple-comparison test (for 
samples of unequal size) was used after the confirmation of homogeneity of variance 
among the groups by Bartlett’s test. For multigroup comparisons with non-Gaussian 
distribution, a Kruskal-Wallis test with Dunn’s test was used. P values of 0.05 or less 
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Supplementary Figure 1 Inhibition of Syk or Jnk do not affect the expression of inflammasome molecules. (a,d,f) Immunoblot analysis of inflammasome molecules or 
(b,c,e) Enzyme-linked immunosorbent assay of IL-18 in peritoneal macrophages (a,d–f), bone marrow-derived macrophages (b), or U937 cells (c) primed with LPS for 4 
h (a), followed by stimulation with nigericin for 90 min (b–d), or alum for 6 h (e,f). The indicated kinase inhibitors were added to the cultures 1 h before stimulation. CL, 
cell lysates; SN, supernatants. Data are shown as the means ± s.d. of triplicate samples of one experiment representative of three independent experiments. Data were 

































































































































































































































































































































































































Supplementary Figure 2 Knockdown of Syk or Mapk8-Mapk9 in primary macrophages. (a,b,e,f) Immunoblot analysis of caspase-1 or (c,d) enzyme-linked 
immunosorbent assay of IL-18 in peritoneal macrophages unprimed (a,b), primed with LPS for 4 h, followed by stimulation with nigericin for 90 min (c,e), or unprimed 
macrophages stimulated with poly(dA:dT) for 3 h (d,f). Macrophages were transfected with siRNAs for 48 h. Control, negative control siRNA; CL, cell lysates; SN, 
supernatants; ND, not detected. Data are shown as the means ± s.d. of triplicate samples of one experiment representative of three independent experiments. Data were 
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Supplementary Figure 3 Syk is not required for NLRP3 inflammasome activation in dendritic cells. (a,b) Enzyme-linked immunosorbent assay of IL-18 or (c,d) 
immunoblot analysis of inflammasome molecules in bone marrow-derived dendritic cells (a,c,d) or bone marrow-derived macrophages (b,e) primed with LPS for 4 h, 
followed by stimulation with nigericin for 90 min. Bone marrow-derived macrophages were prepared using L-cell conditioned medium. CL, cell lysates; SN, 
supernatants. Data are shown as the means ± s.d. of triplicate samples of one experiment representative of two independent experiments. Data were analyzed by two-
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Supplementary Figure 4 Implication that Syk contributes to inflammasome activity through an unknown mechanism. (a–g) Immunoblot analysis of kinases, (h–j) 
enzyme-linked immunosorbent assay of IL-18, or (k) FACS analysis of mitochondrial ROS in peritoneal macrophages primed with LPS for 4 h, followed by stimulation 
with nigericin for the indicated times (a,c,e,g,h,j,k), or unprimed macrophages stimulated with poly(dA:dT) for 3 h (b,d,f,i,j). The kinase inhibitors and BHA (25 mM) 
were added to the cultures 1 h before stimulation (a–e,j,k). The cells were incubated with nigericin for 20 min in the presence of MitoSOX (5 mM) and analyzed on a flow 
cytometer (k). Data are shown as the means ± s.d. of triplicate samples of one experiment. Data shown in e,f,h–k are representative of three independent experiments and 
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Supplementary Figure 5 Requirement of Syk and Jnk for ASC speck formation induced by poly(dA:dT). (a–d) ASC staining or (e,f) immunoblot analysis of ASC in 
peritoneal macrophages primed with LPS for 4 h, followed by stimulation with nigericin for 90 min (a,b), or unprimed macrophages stimulated with poly(dA:dT) for the 
indicated times (c–f). The kinase inhibitors were added to the cultures 1 h before stimulation (c–f). ASC is shown in green, nuclei in blue (a–c). The number of ASC 
speck-positive cell was counted and normalized to that of dimethyl sulfoxide (d). Triton-soluble (S) and Triton-insoluble (I) fractions (right margin; e) or Triton-
insoluble fractions treated with DSS (I + DSS; f). Data are shown as the means ± s.d. of triplicate samples of one experiment. Data shown in c–f are representative of 
three independent experiments and those in a,b are representative of two independent experiments. Data were analyzed by Kruskal-Wallis test with Dunn’s multiple 

































Netphos prediction score 
Supplementary Figure 6 Prediction of phosphorylation sites in mouse ASC. Possible 
phosphorylation sites in the amino acid sequence of mouse ASC were predicted by 

















Supplementary Figure 7 Reconstitution of inflammasome system in HEK293 cells. 
(a, b) Immunoblot analysis of inflammasome molecules in reconstituted HEK293 
cells transfected as described in Fig. 5a,b. 
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Supplementary Figure 8 Involvement of ASC and Jnk in inflammatory responses to MSU and Alum in vivo. (a–f) 
Infiltration of inflammatory cells in the peritoneal cavity induced by intraperitoneal injection of MSU (a–c) or alum 
(d–f) at 6 h after injection. Two hours before and 30 min later administration of the irritants, the mice were 
intraperitoneally treated with Jnk inhibitor. (g–l) Infiltration of inflammatory cells in the peritoneal cavity induced 
by intraperitoneal injection of KC or PBS at 1.5 h after injection. Absolute numbers of PECs (a,d,g,j), Gr-1+ F4/80– 
neutrophils (b,e,h,k), and F4/80+ monocytes and macrophages (c,f,i,l) in the peritoneum were then determined. Data 
are shown as dots, and the bars indicate the means ± s.d. (n = 7 for a–f; n = 5 for g–l; n = 3 for PBS control in g–l). 
Data were analyzed by one-way ANOVA with Bonferroni (a–d,f) or Tukey-Kramer (g–l) multiple comparison test, 
or Kruskal-Wallis test with Dunn’s multiple comparison test (e). NS, no significant difference. * P < 0.05 , ** P < 





Supplementary Table 1 List of kinase inhibitors 
 
Inhibitor Abbreviation Target Final conc. 
 R406 R406 Syk 1 M 
 BAY 61-3606 BAY Syk 10 M 
 Syk inhibitor I SI Syk 1 M 
 PP2 PP2 Src 5 M 
 SP600125 SP JNK 40 M 
 TAT-TI-JIP153-163  TAT JNK 40 M 
 SB203580 SB p38 10 M 
 FR180204 FR Erk 10 M 




Supplementary Table 2 Prediction of kinase-specific phosphorylation sites in ASC from different species 
 
Tested kinase Target protein  Code   Position   Peptide Score 
Syk family  Mouse ASC   Y 144   SVLTEGQYQAVRAET   1.092 
JNK family  Mouse ASC T   29   KFKMKLLTVQLREGY   1.312 
JNK family Mouse ASC T   87   ELAEQLQTTKEESGA   1.625 
JNK family Mouse ASC T   88   LAEQLQTTKEESGAV   1.479 
JNK family  Mouse ASC S   100   GAVAAAASVPAQSTA   1.333 
JNK family  Mouse ASC S   105   AASVPAQSTARTGHF   1.688 
JNK family  Mouse ASC  S   153   AVRAETTSQDKMRKL   1.458 
JNK family  Mouse ASC S   193   LVMDLEQS*******   1.438 
Syk family   Human ASC  Y   146  KVLTDEQYQAVRAEP  1.723 
JNK family   Human ASC  Y   187 ALRESQSYLVEDLERY   1.308 
JNK family   Human ASC  S   106    GIQAPPQSAAKPGLHA   2.500 
JNK family   Human ASC T   154  QAVRAEPTNPSKMRK   1.333 
JNK family   Human ASC T   166    MRKLFSFTPAWNWTC   2.146 
JNK family   Human ASC S   195    LVEDLERS*******   1.542 
Syk family   Zebrafish ASC Y   152    KVITNEDYCTIRNKE  1.892 
JNK family   Zebrafish ASC S   40    QEPRVTKSAIEKLKD  1.354 
JNK family   Zebrafish ASC T   160    CTIRNKETPQKKMRE  5.104 
JNK family   Zebrafish ASC T   170    KKMRELLTGPITCAG  1.521 
  
Supplementary Table 3 List of primers 
 
Primer No.  Primer used for    Direction Sequence  
1   mNLRP3 cloning      Fw    CCTGCGGCCGCAACGAGTGTCCGTTGCAAG  
2   mNLRP3 cloning      Rv    CCTGGTACCCTACCAGGAAATCTCGAAGACTA  
3   mSyk cloning      Fw    AGCTTGCGGCCGCGGGAAGTGCTGTGGACAGCGCC  
4   mSyk cloning      Rv    CTAGAGTCGACTTAGTTAACCACGTCGTAGTAG  
5   mJNK1 cloning      Fw    CAACTATCGATGAGCAGAAGCAAACGTGACAAC  
6   mJNK1 cloning      Rv    CGCACGGATCCTCATTGCTGCACCTGTGCTAAAGG  
7   mJNK2 cloning      Fw    CAACTATCGATGAGTGACAGTAAAAGCGATGG  
8   mJNK2 cloning      Rv    CGCACGGATCCTCACCGGCAGCCTTCCAGGGGTCC  
9   NLRP3-R258W mutant     Fw    CCACTGCTGGGAGGTGAGCCTCAG  
10  NLRP3-R258W mutant     Rv    TCACCTCCCAGCAGTGGATAAAGAA  
11  ASC-S16A mutant      Fw    AACTTGGCCGGGGATGAACTCAAAAAG  
12  ASC-S16A mutant      Rv    ATCCCCGGCCAAGTTTTCAAGAGC  
13  ASC-S58A mutant      Fw    CTTGTCGCCTACTATCTGGAGTCGTATG  
14  ASC-S58A mutant     Rv    ATAGTAGGCGACAAGTTTGTCAGTGAG  
15  ASC-T69A mutant      Fw    GAGCTCGCCATGACTGTGCTTAGAG  
16  ASC-T69A mutant      Rv    AGTCATGGCGAGCTCCAAGCCATAC  
17  ASC-S87A/T88A mutant   Fw    CTGCAAGCCGCTAAAGAAGAGTCTGGA  
18  ASC-S87A/T88A mutant   Rv    CTTCTTTAGCGGCTTGCAGCTGCTCAGC  
  
Primer No.  Primer used for    Direction Sequence  
19  ASC-S92A mutant      Fw   GAAGAGGCCGGAGCTGTGGCAGCTG  
20  ASC-S92A mutant      Rv   CAGCTCCGGCCTCTTCTTTAGTCGT  
21  ASC-S105A/T106A mutant    Fw   CTCAGGCCGCAGCCAGAACAGGACAC  
22  ASC-S105A/T106A mutant    Rv   CTGGCTGCGGCCTGAGCAGGGACACTG  
23  ASC-T125A mutant      Fw   AGGGTCGCAGAAGTGGACGGAGTGCTG  
24  ASC-T125A mutant      Rv   CACTTCTGCGACCCTGGCAATGAGTGC  
25  ASC-T151A/T152A/S153A mutant  Fw   AGAGGCCGCCGCCCAAGACAAGATGAGGAAG  
26   ASC-T151A/T152A/S153A mutant   Rv   CTTGGGCGGCGGCCTCTGCACGAACTGCCTG  
27   ASC-S162A mutant      Fw   AACTTGGCCGGGGATGAACTCAAAAAG  
28   ASC-S162A mutant      Rv   ATCCCCGGCCAAGTTTTCAAGAGC  
29   ASC-T170A mutant     Fw   AACCTGGCCTGCAAGGACTCCCTC  
30   ASC-T170A mutant     Rv   CTTGCAGGCCAGGTTCCAGGATGG  
31   ASC-Y36F mutant      Fw   GAAGGCTTTGGGCGCATCCCACGC  
32   ASC-Y36F mutant     Rv   GCGCCCAAAGCCTTCTCGCAGTTG  
33   ASC-Y144F mutant     Fw   GGACAGTTCCAGGCAGTTCGTGCA  
34   ASC-Y144F mutant     Rv   TGCCTGGAACTGTCCTTCAGTCAG  
35   Deletion of FLAG-tag      Fw   CTACCATGGCGGCCGCGAATTCATCG  
36   Deletion of FLAG-tag      Rv   GCGGCCGCCATGGTAGATCAATTCTGA  
